UDP-glucuronosyltransferase 2B4

BE0003681ProteinHumansUGT2B4

UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite's water solubility, thereby facilitating excretion into either the urine or bile (PubMed:18719240, PubMed:23288867). It is acted on by 22 drugs in DrugBank.

Gene name
UGT2B4
UniProtKB entry
P06133Swiss-Prot
Cellular location
Endoplasmic reticulum membrane
Residues / weight
528 residues · 60,512 Da
Also known as
2.4.1.17 · HLUG25 · Hyodeoxycholic acid-specific UDPGT · UDPGT 2B4 · UDPGTh-1

Resolves to

Protein
UniProtP06133UniProt nameUD2B4_HUMAN
Gene
HGNCHGNC:12553NCBI Gene7363GenBank37589GeneCardsUGT2B4
Pharmacology
KEGGhsa:7363
Drugs

What you can answer from here — as of September 07, 2019

22DrugsApproved to experimental, with action, bond type and pharmacological action
Sign in
18Metabolic reactionsDrug transformations it catalyses, substrate to product
Sign in
1GO termFunction, process and component, as structured annotations
Sign in
1Pfam domainDomain architecture mapped to Pfam families and clans
Sign in
44+ReferencesStructured and connected to the statements they support
Sign in

Which approved drugs act on UDP-glucuronosyltransferase 2B4, how selective are they, and which programs against it are still in active trials?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In